Impact of Vaccination on 14 High-Risk HPV Type Infections: A Mathematical Modelling Approach. by Vänskä, Simopekka et al.
 
 
This document has been downloaded from  
TamPub – The Institutional Repository of University of Tampere 
 
 
Publisher's version 
 
The permanent address of the publication is http://urn.fi/URN:NBN:fi:uta-
201310011425  
  
Author(s):  
Vänskä, Simopekka; Auranen, Kari; Leino, Tuija; Salo, Heini; 
Nieminen, Pekka; Kilpi, Terhi; Tiihonen, Petri; Apter, Dan; Lehtinen, 
Matti 
Title:  Impact of Vaccination on 14 High-Risk HPV Type Infections: A Mathematical Modelling Approach. 
Year:  2013 
Journal 
Title:  Plos ONE 
Vol and 
number:  8 : 8  
Pages:  1-10 
ISSN:  1932-6203 
Discipline:  Health care science 
School 
/Other Unit:  School of Health Sciences 
Item Type:  Journal Article 
Language:  en 
DOI:  http://dx.doi.org/10.1371/journal.pone.0072088  
URN:  URN:NBN:fi:uta-201310011425 
URL:  http://dx.doi.org/10.1371/journal.pone.0072088  
 
 
 
 
All material supplied via TamPub is protected by copyright and other intellectual 
property rights, and duplication or sale of all part of any of the repository collections 
is not permitted, except that material may be duplicated by you for your research use 
or educational purposes in electronic or print form. You must obtain permission for 
any other use. Electronic or print copies may not be offered, whether for sale or 
otherwise to anyone who is not an authorized user. 
Impact of Vaccination on 14 High-Risk HPV Type
Infections: A Mathematical Modelling Approach
Simopekka Va¨nska¨1,2*, Kari Auranen1, Tuija Leino1, Heini Salo1, Pekka Nieminen3, Terhi Kilpi1,
Petri Tiihonen1, Dan Apter4, Matti Lehtinen2
1Department of Vaccination and Immune Protection, National Institute for Health and Welfare (THL), Helsinki, Finland, 2 School of Public Health, University of Tampere,
Tampere, Finland, 3Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Helsinki, Finland, 4 Sexual Health Clinic, Family Federation of Finland,
Helsinki, Finland
Abstract
The development of high-risk human papillomavirus (hrHPV) infection to cervical cancer is a complicated process. We
considered solely hrHPV infections, thus avoiding the confounding effects of disease progression, screening, and
treatments. To analyse hrHPV epidemiology and to estimate the overall impact of vaccination against infections with
hrHPVs, we developed a dynamic compartmental transmission model for single and multiple infections with 14 hrHPV
types. The infection-related parameters were estimated using population-based sexual behaviour and hrHPV prevalence
data from Finland. The analysis disclosed the important role of persistent infections in hrHPV epidemiology, provided
further evidence for a significant natural immunity, and demonstrated the dependence of transmission probability
estimates on the model structure. The model predicted that vaccinating girls at 80% coverage will result in a 55% reduction
in the overall hrHPV prevalence and a higher 65% reduction in the prevalence of persistent hrHPV infections in females. In
males, the reduction will be 42% in the hrHPV prevalence solely by the herd effect from the 80% coverage in girls. If such
high coverage among girls is not reached, it is still possible to reduce the female hrHPV prevalence indirectly by the herd
effect if also boys are included in the vaccination program. On the other hand, any herd effects in older unvaccinated
cohorts were minor. Limiting the epidemiological model to infection yielded improved understanding of the hrHPV
epidemiology and of mechanisms with which vaccination impacts on hrHPV infections.
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Introduction
The development of high-risk human papillomavirus (hrHPV)
infection to cervical cancer is a complicated process including
transmission and clearance of infections with different HPV types
as well as progression and regression of associated lesions.
Furthermore, cytological screening and treatment of lesions
interfere with the natural course of disease progression and
provide only incomplete information about the underlying
processes. Vaccination is considered to protect against cervical
cancer by preventing infections with a subset of hrHPV [1,2]. Two
currently available vaccines have shown significant protection
against two target types (HPV16, HPV18), but also some
protection against a number of other, up to 4 hrHPV types
(HPV31, HPV33, HPV45, HPV51), and 43% to 93% efficacies
against all cervical intraepithelial lesions of grade 3 (CIN3), the
immediate precursor of cervical cancer [2,3,4,5,6]. The highest
vaccine efficacies have been reported for the bivalent vaccine in
baseline HPV-naı¨ve group [6]. Preliminary information about the
effectiveness of HPV vaccination programs can be gained from
hrHPV prevalence much earlier than the cancer incidence would
change. In addition, possible vaccine failures and type replacement
would appear first on the infection level [7].
To understand HPV transmission and the impact of vaccination
on the hrHPV infection epidemiology, it is beneficial to
disentangle the infection and disease processes thus avoiding the
confounding effects of screening and treatment policies. For
example, the findings of precancerous lesions depend strongly on
screening activity, and so, if infection-related parameters are
estimated together with the disease process, the estimates are likely
affected by possible errors and uncertainties in the screening
model. A separate infection model facilitates the analysis of the
characteristics of hrHPV infections, including natural immunity
against infection and differences across hrHPV types in clearance
and vaccine efficacy. An early model of HPV epidemiology
separated HPV transmission and the disease process [8]. Since
then epidemiological models of HPV have typically included both
transmission and disease progression (e.g., [9,10,11,12,13,14,15]))
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although some have focused on the parameters of hrHPV infection
[11]. In this work, we address only HPV infections.
We present a model for 14 hrHPV types, calibrated to
population-based data on hrHPV prevalence in Finnish women
[16] and cohort data of type-specific hrHPV infection in the
control arm of the population based PATRICIA phase III vaccine
study [2] in Finland. The HPV vaccination program is planned to
start in Finland in autumn 2013. To the best of our knowledge,
this is the first compartmental HPV transmission model that
includes single and multiple infections with a large number of
hrHPV types, even though corresponding micro-simulation
models exist [17,18,19,20]. In general, compartmental models
are more suitable for analysing the role of parameter uncertainty
than individual-based models as there is no stochastic variation
across model outputs. An earlier model predicting the impact of
HPV vaccination on cervical cancer [9] was fitted to Finnish
seroprevalence data of HPV16, which approximates the cumula-
tive incidence with moderate sensitivity. Our model was used to
investigate the relative roles of the key characteristics of hrHPV
epidemiology and to predict the impact of vaccination on the
hrHPV infection epidemiology under different vaccination
scenarios.
Materials and Methods
For each single hrHPV type, we considered HPV transmission
in an ‘‘SIRS+V’’ model, dividing the population into four type-
specific epidemiologic states: S for susceptible, I for infectious, R
for recovered and V for vaccine-protected individuals. The
population was further stratified into behavioural subpopulations.
In the following, we outline the parameter sources and new
modelling features, including the contact structure based on the
lifetime partner number, and the construction of a multiple-type
transmission model from single-type models (Figure 1). File S1
includes the detailed model specification as well as all data that
were used as input in the analyses of this paper. The transmission
model was programmed with MATLAB and the simulations were
run on a standard laptop.
Contact Structure
Sexual activity was assumed to depend on age, gender, and
lifetime partner number. Let X (n,vDg,a; t) be the proportion of
individuals with n (n~0,1,2,:::) lifetime partners and vaccination
status v (v=vaccinated/unvaccinated) among those of gender g
(g= f/m= female/male) and age a at time t. Assume that the
lifetime partner number in the (g,a) subpopulation does not
depend on the vaccination status or the calendar time. Then
X (n,vDg,a; t)~X (vDg,a; t)X (nDg,a), ð1Þ
where X (vDg,a; t) is the proportion of vaccinated in the (g,a)
subpopulation at time t. The partner number distribution X (nDg,a)
was obtained from a continuous-time Markov process with the
new partner acquisition rates as the transition rates. The new
partner acquisition rate a~a(g,a,n) is the rate (hazard) at which
an individual in the (g,a,n) subpopulation acquires new partners.
The entry age in the model was 10 years, at which age all
individuals have n~0 lifetime partners. Based on the partner
number and vaccination status, a model for the distribution of
contacts between the different subpopulations was constructed
according to the age distribution of heterosexual pair formation
and the proportionate mixing principle.
Sexual Behaviour Parameters
The new partner acquisition rate a(g,a,n) and the correspond-
ing partner number distribution (Figure 2, Figures S1–S3 in File
S1) were estimated from the School Health Promotion (SHP)
Study 2008–2009 [21], the FINSEX 2007 study [22], and national
data on age at marriage [23]. The biannual SHP study covers over
half of the 14–18 years old population in Finland. FINSEX 2007 is
a population based sampling survey of 2590 adults, and the
register-based marriage statistics includes all new marriages in
Finland in 2008.
The new partner acquisition rate a(g,a,n) for n = 0, i.e., for the
first partner, was estimated from the age-specific proportions
X (0Dg,a) of those with no lifetime partners in the SHP study and
the FINSEX 2007 data. For n .0, the estimation of a was based
on the proportions X (nDg,a) in the SHP study (teenagers) and on
the annual partner number data in FINSEX 2007 (adults). We
applied a likelihood function based on weighted squares of
residuals and a prior with positivity and smoothness assumptions.
The data are provided in the Tables S1–S2 in File S1.
The age-specific distribution of the partner age was taken to be
a Beta distribution with the age-specific mean and variance
estimated from the marriage statistics (Table S3 and Figure S4 in
File S1). For teenagers, means and variances were extrapolated
from the results for adults.
Multiple hrHPV Type Infections
Infections with different hrHPV types were assumed to occur
independently within a host. This corresponds to an assumption
that any dependencies among type-specific infections at the
population level are due to heterogeneity in the sexual behaviour
and vaccination status. Specifically, in each (n,vDg,a) subpopula-
tion, infections with different hrHPV types j (j~1, . . . ,J) were
considered independent, based on similar behavioural histories.
Hence, the prevalence for all hrHPV infection in a (n,vDg,a)
subpopulation at time t is
Figure 1. Data and Modelling Overview. The parameters of the
sexual contact structure were estimated from the School Health
Promotion study [21], FINSEX 2007 study [22], and marriage statistics
[23]. The type-specific clearance of new infections was estimated from
the control arm of PATRICIA phase III HPV vaccine study in Finland [2].
The contact structure and the type-specific clearance rates were used as
input for the single-type transmission models. The multiple-type
transmission model ties together the single-type models and produces
the hrHPV prevalence, which was fitted to the age-specific hrHPV
prevalence data [16] by calibrating three model parameters (transmis-
sion probability, natural immunity, and the clearance rate of persistent
infections).
doi:10.1371/journal.pone.0072088.g001
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Ihr(n,vDg,a; t)~1{ P
J
j~1
(1{Ij(n,vDg,a; t)), ð2Þ
where Ij(n,vDg,a; t) is the prevalence of type j. The prevalence of
all hrHPV types in gender g at age a at time t is
Ihr(g,a; t)~
X
n,v
X (n,vDg,a; t)Ihr(n,vDg,a; t): ð3Þ
By equations (2) and (3), it is enough to construct the transmission
model separately for each hrHPV type in order to compute the all
hrHPV prevalence.
Single-type Transmission Model
Figure 3 presents the structure of the transmission model for a
single hrHPV type (for formulae, see Table S4 in File S1). The
force of infection was divided into primary and secondary
components, according to whether infection is acquired from a
new partner or from the current one who has sex with someone
else (secondary contact). The importance of the secondary force of
infection was controlled with a weight parameter c, which
describes the intensity of individuals making secondary contacts.
The natural history of HPV infection was described with the
infection-age (t, time since infection) alone. In females, hrHPV
types were assumed to clear with an infection-age dependent rate
g(t). The clearance of transient (new) infections was assumed to
slow down type-specifically with t, taking g(t) to be a Weibull rate.
We assumed that 5% of infections acquired more than 2 years ago
become annually ‘‘old’’ with a common clearance rate (gpers) for all
types (for implementation, see Figures S5–S6 in File S1). We call
these ‘‘old’’ infections persistent infections in the following. In
males, we assumed a constant type-specific clearance rate
equalling the first year average of female rates [24]. After
clearance, individuals were assumed to acquire natural immunity
which wanes with rate w.
Vaccine-induced protection was modelled according to the
‘‘take’’ model. Among vaccinated individuals, vaccine efficacy thus
determines the proportion moved from the susceptible state S to
the completely vaccine-protected state V at the vaccination age (12
years). The duration of vaccine-induced protection was modelled
Figure 2. The Pattern of Sexual Contacts in Finland. Upper panel: the age-specific annual mean numbers of new sexual partners by lifetime
partner number with the observed numbers (asterisks). Lower panel: the age-specific stratification of the population by lifetime partner number and
the corresponding data (asterisks).
doi:10.1371/journal.pone.0072088.g002
Modelling 14 High-Risk HPV Type Infections
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e72088
through a waning immunity so that after an initial period of full
protection for Tvac years immunity subsequently wanes in an
average of mvac years. We assumed that HPV vaccination does not
change the natural history of HPV infections, e.g., the clearance
rates.
HPV-related Parameters
For the transient (new) infections in females, the infection-age
dependent hrHPV type-specific clearance rates were estimated
from the Finnish unvaccinated control arm of the PATRICIA
Phase III vaccine study [2]. The types were grouped to slow,
moderate and fast clearance types (Table S5 and Figures S7–S8 in
File S1).
The multiple-type transmission model was calibrated to the age-
specific all hrHPV prevalence (Figure 4A, Table S6 in File S1) in
the hrHPV screening trial [16]. These data include a population-
based, non-type-specific, hrHPV prevalence among 75,000
women at screening ages 25, 30, ..., 65 in Finland in the
prevaccination years 2004–2008. The prevalence data on teenag-
ers came from the PATRICIA vaccine study. Three parameters
were calibrated: the transmission probability b (probability to
acquire HPV infection from a new infected partner), the clearance
rate gpers of persistent infections, and the waning rate w of natural
immunity. The model outcome (age-specific all hrHPV preva-
lence) was fitted to the data by sampling a weighted squares based
posterior distribution. The weights were derived from the annual
variation of age-specific hrHPV prevalence. During the calibra-
tion, the parameters of sexual behaviour, clearance of new
infections, and the weight c for the secondary force of infection
were kept fixed.
Effectiveness of Vaccination
The effectiveness of HPV vaccination was measured as a
relative reduction in the prevalence of individual hrHPV types (for
type-specific effectiveness) and all hrHPV types. The reductions
were based on comparison of the pre- and post-vaccination steady
states. The effectiveness was calculated among females 10–70
years of age and separately for the maximum age-specific
prevalence.
Different vaccination characteristics were analysed as alterna-
tive scenarios. In the base-case (Table S7 in File S1), the vaccine
efficacies against the vaccine and non-vaccine types (Table 1) were
close to the best reported values (baseline HPV-naı¨ve group in [4]).
The vaccine and vaccination scenarios were [6]: higher/lower/no
cross-protection, longer/shorter protection, and different vaccina-
tion strategies (Table 2).
To study indirect protection (herd effect), the prevalence of
infection was first determined without the transmission model
assuming only direct protection: the prevalence of hrHPV types
were kept unchanged in the non-vaccinees and set according to
the vaccine efficacies in the vaccinees. The importance of indirect
protection was then assessed with the given coverage of
vaccination as the difference between the steady-state hrHPV
prevalences under the two scenarios (the full model vs. only direct
protection).
Alternative Model Settings
The impacts of different model assumptions were investigated
by comparison of different model settings (Table 3). The model
was re-calibrated for each model setting. The weight c for the
secondary force of infection was assigned values from 0 to 0.8
(base-case c=0.4). The duration of natural immunity was varied
from lifelong (SIR, susceptible-infected-recovered model) to very
short (a model closer to SIS) by setting w=0, and 0.2, respectively,
and the remaining two calibration parameters were re-estimated.
To study the sensitivity to the peak incidence of annual new
partners, the annual new partner numbers at age 20–24 were
increased by 20%.
Figure 3. Transmission Model Structure for a Single HPV Type. The vertical flow corresponds to changes in the epidemiologic states
susceptible (S), infectious (I), recovered (R), and vaccine-protected (V). The flow from left to right corresponds to an increasing lifetime partner
number (n). The arrows describe possible transitions between different states: 1. Acquisition of a new partner without acquiring infection; 2.
Acquisition of a new partner with acquiring infection (primary force of infection); 3. Acquisition of infection from the current partner (secondary force
of infection, for n .0 only); 4. Clearance of infection; 5. Waning natural immunity; 6–7 and 10. Acquisition of a new partner for infected, recovered,
and vaccine protected; 8. Take of vaccine protection; 9. Waning vaccine induced protection. The formulae for all transition rates are presented in File
S1.
doi:10.1371/journal.pone.0072088.g003
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The performance of each model setting was evaluated with a
weighted sum of squared residuals (WSR), computed from the
hrHPV prevalence. A small (large) WSR value means that the
model fit is good (poor), i.e., the data agree (do not agree) with the
model setting assumptions.
Results
The transmission model reproduced accurately the observed
population prevalence of hrHPV in Finland (Figure 4A). All three
calibration parameters were identifiable in the base-case: the
transmission probability was b~0:75 (with standard deviation
SD=0.01), gpers%2:6% (SD 0.5%) of persistent infections cleared
annually, and only w%3:7% (SD 0.6%) of recovered individuals
lost natural immunity per year. The estimated patterns of sexual
contacts agreed well with the population-based data (Figure 2).
According to the model, at the sexually most active ages about one
fourth of women with hrHPV were infected with multiple types.
The proportion decreased with age.
Clearance of Transient (New) HPV Infections
Based on the cohort data [2], HPV16 formed slow, HPV18,
HPV31, HPV33, and HPV52 moderate, and the other hrHPV
types fast clearance groups. The clearance of infections slowed
down with infection-age (i.e. the Weibull shape parameters were
less than one, see Figure S8 in File S1). The mean (median)
Figure 4. The Age-specific High-risk HPV (hrHPV) Prevalence in the Steady-state Before and After Vaccination. Unless otherwise
stated, the results pertain to females under the base-case scenario. (a) The model prediction on the current hrHPV prevalence (upper curve) with the
observed data (asterisks). The lower curves show the prevalence for three different single hrHPV types with low, moderate and fast clearance of
infection (see Materials and Methods); (b) the prevalence of hrHPV and persistent hrHPV before and after vaccination; (c) hrHPV prevalence at
different times since the onset of the vaccination program; (d) hrHPV prevalence in females and males, before and after vaccination; (e) HPV16
prevalence under different vaccine scenarios, waning vaccine protection induces a second peak in the prevalence curve; (f) model fits to hrHPV data
under different waning rates of natural immunity (base-case, SIR, 0.2 1/year waning rate) and the corresponding post-vaccination prevalences.
doi:10.1371/journal.pone.0072088.g004
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duration of infection for the slow, moderate, and fast clearance
groups were 23(12), 12(6), and 7(4) months, and 4.4%, 2.0%, and
0.5% of these infections became eventually persistent, respectively.
Effectiveness of HPV Vaccination
Unless otherwise stated, all results below apply to females
between 10 and 70 years of age. Before vaccination, the
prevalence (maximum prevalence) of hrHPV and of persistent
hrHPV was 9.5% (30.9%) and 2.7% (4.2%), respectively (Table 1).
Under the base-case vaccination scenario (80% vaccination
coverage among women; wide range of type-specific protection
against HPV16, HPV18, HPV31, HPV33, HPV45, and HPV51
(Table 1); 20 years duration of vaccine induced protection (Tvac)
waning on average in the next 20 years (mvac)), the steady-state
prevalence was 4.3% (14.3%), and 1.0% (1.4%), for hrHPV and
persistent hrHPV, respectively (Table 1, Figure 4B). The cross-
protection explained about 1/3 of the effectiveness of vaccination
against hrHPV. Among individual HPV types, the absolute
reduction in prevalence was highest for HPV16, but the relative
effectiveness of vaccination was higher for the faster clearing HPV
types (18, 45, and 51) than for the slowly clearing HPV16 (Table 1).
The proportion of persistent infections increased with age both
in the pre- and postvaccination situations (Figure 4B). The
effectiveness of vaccination against any individual hrHPV type
depended on the clearance rate, but was similar against infection
and persistent infection. However, the effectiveness was better
against all persistent hrHPV infections (64.5%) as compared to all
hrHPV infections (54.6%).
HPV vaccination separates the population into vaccinated and
unvaccinated birth cohorts (Figure 4C). In practice, the unvacci-
nated birth cohorts do not benefit from vaccination. Even many
decades after the start of vaccination program, only unvaccinated
cohorts with ages close to the vaccinated ones experience a minor
reduction in hrHPV prevalence. In contrast, the prevalence
among the vaccinated birth cohorts is close to the eventual steady-
state already after 10 years of starting the vaccinations and at the
steady-state after 20 years.
In the new steady-state, among females indirect protection
explained about 1/3 of the effectiveness of vaccination against
hrHPV in the base-case scenario (Table 2). In males, the decrease
in hrHPV prevalence was solely due to indirect protection. Among
males between 10–70 years of age, the hrHPV prevalence was
7.2% before the vaccination program, and 4.2% in the post-
vaccination steady state, corresponding to 42.3% effectiveness of
vaccination (Figure 4D).
Vaccination Scenarios
Table 2 summarises the sensitivity of model predictions to
different vaccine and vaccination scenarios. Under each of the
scenarios associated with weaker vaccine impacts (lower cross-
protection with vaccine efficacy 50% against type 31, and 0
against other non-vaccine types; shorter Tvac= mvac = 10 years
protection for all types; lower 60% coverage for girls), the
effectiveness of vaccination was significantly worse than in the
base-case. With shorter protective duration for the non-vaccine
types the scenario was closer to the base-case than the
corresponding shorter protective duration scenario for all types.
A moderate coverage among girls was compensated by vaccinating
also boys (girls 60%+boys 40%). However, this was not the case
with weak vaccine-induced cross-protection or short protective
duration for all types. Increasing the coverage among girls from
80% to 90% corresponded to the same effectiveness among
females as vaccinating 80% girls and 40% of boys.
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Waning of vaccine-induced protection was associated with a
second increase in the prevalence of some HPV types in older
women (e.g. Figure 4E for HPV16). A shorter duration of
protection brought the increase earlier and more notable. The
post-vaccination prevalence, however, remained smaller than the
pre-vaccination prevalence for all ages.
Alternative Model Settings
The model outcomes (Table 3, Figure 4) in the base-case
analysis, in which the natural immunity waning rate was one of the
calibrated parameters, were closer to those obtained when
assuming life-long immunity (SIR) than very short durations of
immunity (i.e. models close to SIS). In particular, the SIS model
was not supported by data (large WSR). Interestingly, where the
model strongly suggested a long-lasting natural immunity in
women, the female hrHPV prevalence data were not informative
about the duration of natural immunity in males. There was no
significant difference in the model fit between SIS and SIR models
applied only to males, but using SIS for males produced a better
effectiveness of vaccination.
As the weight for the secondary force of infection was varied,
the calibrated value for transmission probability changed con-
trariwise. Overall, however, the assumptions about the secondary
force of infection had only little impact on the model fit or on the
predicted effectiveness of vaccination as shown by the stable WSR
(Table 3). Increasing the number of annual new partners in the
most active adults (age 20–24) by 20% implied a decrease in the
transmission probability but the other parameters and the
effectiveness of vaccination remained unchanged. The model fit
was, however, worse under this scenario (larger WSR, Table 3).
Parameter Uncertainty
The influence of parameter uncertainty in model predictions
was small (Table S8 and Figure S9 in File S1). There was much
more variation in the model outcome across different vaccination
scenarios and model settings.
Discussion
We constructed a compartmental transmission model for single
and multiple infections with 14 hrHPV types to predict the overall
effectiveness of different vaccination strategies against hrHPV
infection. The model reproduced adequately the current hrHPV
prevalence in Finland. Assuming 80% vaccination coverage
among girls, the model predicted approximately 55% reduction
in the hrHPV prevalence and a higher 65% reduction in persistent
hrHPV prevalence in females. For males, not vaccinated in the
base-case, and females the model predicted 42% and 17%
decreases in hrHPV prevalence, respectively, solely due to indirect
protection (herd effect). The herd effect from vaccinating also
males compensated a low coverage of vaccination among women.
Several lessons on the HPV natural history were learned by
relating data on sexual behaviour to age-specific hrHPV
prevalence through modelling. First, the considerably high hrHPV
prevalence among older women can mainly be explained by
persistent hrHPV infections. In particular, the level of sexual
activity alone could not account for the slowly decreasing hrHPV
prevalence in women of age 40 and over. Second, the rapid
decrease in the prevalence after 25 years of age is due to both the
decreasing sexual activity and acquired natural immunity. Third,
to adequately describe the peak in the hrHPV prevalence in young
women (ages 20–25), the transmission probability needs to be
relatively high.
The presence of persistent hrHPV infections has important
implications for the effectiveness of HPV vaccination, consistent
with the critical role of the duration of infection in cervical
carcinogenesis [25]. Our model assumed a prophylactic vaccine
and therefore the effectiveness against infection and the effective-
ness against persistent infection for any individual hrHPV type
were at the same level. However, because the licensed vaccines
include HPV16 and HPV18, which are slower clearing and thus
more likely to become persistent, HPV vaccination appeared to
have better effectiveness against all persistent hrHPV than against
all hrHPV infection. This agrees with the observation of increasing
vaccination effectiveness against increasingly severe cervical lesions
[2,3]. Our model with multiple types could thus explain the
difference in the effectiveness against all hrHPV and all persistent
hrHPV without the need of an additional mechanism, e.g.
assuming that the vaccine would also prevent infection becoming
persistent.
A high rate of waning immunity against hrHPV infection is
unlikely as the model was not able to explain the rapid decrease in
hrHPV prevalence after the peak prevalence under such a
scenario. This does not rule out re-infections with the same type
Table 3. Alternative Model Settings.
Setting Model fit Post-vaccination prevalence (%)
WSR gpers mean (SD) b mean (SD) w mean (SD)
hrHPV infection prev.
(max)
hrHPV pers.inf. prev.
(max)
Base-case 3.0 0.026 (0.005) 0.747 (0.012) 0.037 (0.006) 4.29 (14.28) 0.97 (1.42)
w= 0 (SIR) 19.7 0.007 (0.002) 0.808 (0.012) – 4.54 (15.49) 1.35 (1.82)
w= 0.2 (,SIS) 49.8 0.294 (0.048) 0.623 (0.006) – 2.75 (9.84) 0.12 (0.36)
c= 0 2.6 0.026 (0.004) 0.871 (0.017) 0.044 (0.005) 4.17 (13.74) 0.99 (1.45)
c= 0.8 3.3 0.026 (0.005) 0.671 (0.010) 0.034 (0.006) 4.35 (14.48) 0.97 (1.40)
+20% partners 14.8 0.021 (0.005) 0.658 (0.014) 0.037 (0.008) 4.34 (16.28) 1.07 (1.55)
Male SIS 6.4 0.020 (0.003) 0.653 (0.008) 0.008 (0.001) 3.84 (12.46) 0.97 (1.37)
The model fit and outcomes (post-vaccination prevalence) under different model assumptions about duration of natural immunity (1/w), weight of the secondary force
of infection (c base-case= 0.4), increased new partner acquisition rate for young adults (+20% partners), and different natural immunity waning model (SIS) only for
males. The measure of model fit is a weighted sum of squared residuals (WSR). The calibrated model parameters: clearance rate of persistent infection (gpers),
transmission probability per partnership (b), waning rate of natural immunity (w). The mean and standard deviation (SD) are given for each parameter. The high-risk HPV
(hrHPV) infection includes both transient and persistent infections (pers.inf.).
doi:10.1371/journal.pone.0072088.t003
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[26] as individuals may still lose their immunity. However, the
dynamics of hrHPV appears to be closer to models with life-long
immunity (SIR) than models without any immunity (SIS). With
any given levels of vaccination coverage and vaccine efficacy, the
SIR model sets a lower bound for the effectiveness of vaccination
as the immunisation needs to replace the lifelong natural immunity
with vaccine-induced protection. Nevertheless, the predicted
overall effectiveness of HPV vaccination was significant.
Findings about a high transmission probability and a long
duration of natural immunity are consistent with previous
estimates, e.g., in [11,14]. However, model simplifications such
as not modelling condom use, smoking, and in our case also
cervical cancer screening, were included implicitly in the
calibration parameters. Note that similar issues apply also when
corresponding parameters are estimated from trial data. For
example, in a screening-based study [27], the clearance of hrHPV
types was slower than what we estimated for a younger study
population [2]. The difference can be explained with different
proportions of persistent infections in the study populations. As a
corollary, all parameters should be interpreted within the model
context.
The limited herd effect in the older unvaccinated birth cohorts
is due to the relatively narrow age-distribution of contacts.
Moreover, during the first few years after the start of a vaccination
program, when the vaccinated cohorts are still young, the
direction of the HPV infection is mainly from older (unvaccinated)
age cohorts to younger (vaccinated) ones, and the older age
cohorts do not really benefit from the vaccination program.
Sexual networks [28] were modelled through a secondary force
of infection. The estimates of the weight of secondary force of
infection and the transmission probability (b) were coupled. If the
secondary force of infection was given less (more) weight, then, the
transmission probability was estimated higher (lower) so that the
narrower (wider) paths of transmission were compensated.
Nevertheless, this interplay had only a little influence on the
predicted effectiveness of vaccination. The influence of a
secondary force of infection might be higher with a different
sexual behaviour pattern.
The clearance of hrHPV types was modelled to depend on
infection-age. Our observation of the clearance slowing down with
infection-age is consistent with a previous analysis, in which the
infection-age dependent clearance rates were also modelled in a
single HPV16 type mode [10]. Naturally, changing the definition
of persistent infections would change the estimate of the clearance
rate of persistent infections.
Interactions between different hrHPV types were modelled in
the simplest way by assuming independence of types within a host
(i.e., no natural infection/immunity derived cross-protection or
within-host competition between different types). In addition, all
three calibrated parameters were considered common to all
hrHPV types. In our approach, variation in the hrHPV prevalence
between types before vaccination was thus solely due to differing
clearance rates. This was partly due to the fact that type-specific
hrHPV prevalence data at the screening ages were not available.
Nevertheless, the model was able to produce differences in the
persistence between hrHPV types, in agreement with known
differences in their oncogenicity, as well as a higher effectiveness of
vaccination against all persistent hrHPV infection.
Limiting the model to infection without considering progression
and screening simplified the analysis. It also makes our results
generalisable to different countries, although they were based on
data from Finland, as any differences in screening policies could be
avoided. It should be noted that rapid changes, e.g., in HPV16
infection epidemics have occurred in Finland [29]. However,
possible changes in sexual behaviour will have a much faster effect
on hrHPV incidence than on the cancer incidence, and hence, the
steady state assumption according to which the current hrHPV
prevalence data correspond to the current sexual behaviour is at
least partially justified.
Heterogeneity in sexual activity was modelled with an evolving
lifetime partner number instead of predetermined sexual activity
groups. Importantly, the lifetime partner number is a measurable
variable, whereas the activity group is always a hyperparameter
which cannot be observed directly. In our model, individuals with
many lifetime partners correspond to high activity groups. We
modelled HPV transmission in the heterosexual pair formation
only. Relaxing the heterosexuality assumption might decrease the
predicted herd effect [30] as the infection would have alternative
paths to transmit.
The model predictions on the effectiveness of vaccination were
not sensitive to different relevant model settings, in which the
model fitted well to data. The only exception regarded the
duration of natural immunity in males, for which the base-case
was close to the lower bound for the effectiveness. Conversely,
vaccination scenarios had much higher impact on the effective-
ness. A suboptimal vaccine or vaccination program yielded
remarkably worse effectiveness of vaccination. However, the low
impact of a moderate (60%) vaccination coverage among girls
could be compensated by the herd effect through vaccinating a
reasonable proportion (40%) of boys.
There are some caveats in our analysis that should be
highlighted. First, limiting the analysis to HPV infections and
ignoring screening of cervical cancer, besides simplifying the
analysis, is also a limitation, because some infections are treated
after screening. Second, the model assumption of independent
types means that any interactions between HPV types could not be
addressed, including the possibility of cross-protection [31]. Third,
it is possible that the vaccine-induced protection against some
HPV types differ from those considered in our scenarios.
Our analysis has several implications. The ability of hrHPV to
persist, the long natural immunity, and high transmissibility imply
that both vaccination coverage and vaccine efficacy need to be
high for elimination of infection. As a consequence of the
considerable remaining prevalence of hrHPV infection, it seems
necessary to continue cervical cancer screening in vaccinated
populations, although possibly in new optimised forms. Especially,
due to only a minor herd effect from vaccinated to unvaccinated
cohorts, screening should be continued intensively among the
unvaccinated cohorts. The increasing proportion of persistent
infection with age should also be taken into account when
developing screening programs. The analysis also suggests that
monitoring hrHPV infection could be advantageous as part of
cervical cancer screening.
In conclusion, vaccination of girls is expected to reduce the
prevalence of all persistent hrHPV even more than the all hrHPV
prevalence. If the coverage of vaccination among girls is low, it is
more efficient, when female hrHPV prevalence is considered, to
increase the coverage among girls than vaccinate boys. If this fails,
however, it is possible to reduce the female hrHPV prevalence
indirectly by vaccinating also boys. If the start of HPV vaccination
program is postponed one can not rely on a herd effect to get
protection afterwards for the unvaccinated, older bith cohorts.
Finally, outcomes from the current transmission model can be
applied as inputs to a disease progression model. Combinations of
transmission and disease progression models are needed in
optimising comprehensive HPV disease prevention programs.
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